Quantification of SAA1 and SAA2 in lung cancer plasma using the isotype-specific PRM assays.
about
Parallel Reaction Monitoring: A Targeted Experiment Performed Using High Resolution and High Mass Accuracy Mass SpectrometryAdvances in targeted proteomics and applications to biomedical researchIntegration of Breast Cancer Secretomes with Clinical Data Elucidates Potential Serum Markers for Disease Detection, Diagnosis, and Prognosis.Vaccination via Chloroplast Genetics: Affordable Protein Drugs for the Prevention and Treatment of Inherited or Infectious Human DiseasesProteomic discovery and verification of serum amyloid A as a predictor marker of patients at risk of post-stroke infection: a pilot study.Serum amyloid A expression in the breast cancer tissue is associated with poor prognosis.Mass Spectrometry Analysis of Lysine Posttranslational Modifications of Tau Protein from Alzheimer's Disease Brain.Development of a sequential workflow based on LC-PRM for the verification of endometrial cancer protein biomarkers in uterine aspirate samples.Proteome Characterization of Human Pancreatic Cyst Fluid from Intraductal Papillary Mucinous Neoplasm by LC/MS/MS.Clinical applications of MS-based protein quantification.Parallel reaction monitoring using quadrupole-Orbitrap mass spectrometer: Principle and applications.Determination of differentially regulated proteins upon proteasome inhibition in AML cell lines by the combination of large-scale and targeted quantitative proteomics.Clinical translation of MS-based, quantitative plasma proteomics: status, challenges, requirements, and potential.Quantification of Cardiovascular Disease Biomarkers in Human Platelets by Targeted Mass Spectrometry.Exploring the expression bar code of SAA variants for gastric cancer detection.Serum amyloid A1 in combination with integrin αVβ3 increases glioblastoma cells mobility and progression.
P2860
Q26775066-1810D496-C8B2-4197-863F-BD7CBB25EF2AQ28066912-52D9C44D-D7B2-4184-96E9-01D84E3B7323Q31111254-26541944-FEAD-44C8-B447-A734BAF4A4C8Q33870122-E034CC38-B929-40EC-9CA7-B433AB38E038Q33896288-30734C01-9B96-40DC-ABE9-AA6FE13591B7Q37392583-441E56BB-08BD-4868-90F2-7B16C9ED4D19Q37572010-424782A4-2903-4962-A1E7-0153AA5DFDA6Q37619708-9F2A15AA-3061-48A0-B777-89701D05DC4CQ38372053-DC53FF4F-5241-4E19-AB51-CA99989AC776Q38802991-A7135677-E97C-4C2F-8BAD-494ECE384D4FQ38825316-9F5B1B14-A879-4AEB-8469-AE6E8EBD6299Q39317321-1D504753-FFAD-4D49-B04A-7BA6577765FDQ39657160-A6928A8D-0A85-4A4C-8449-8707CA642D22Q47160415-71E1F0A6-DC79-46ED-90F8-287FD66BCC94Q48158874-C82C3258-4E97-4280-9137-763516398801Q52722719-85EF085D-B8F0-40B2-B5D8-5DDD903D93AC
P2860
Quantification of SAA1 and SAA2 in lung cancer plasma using the isotype-specific PRM assays.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Quantification of SAA1 and SAA ...... e isotype-specific PRM assays.
@en
type
label
Quantification of SAA1 and SAA ...... e isotype-specific PRM assays.
@en
prefLabel
Quantification of SAA1 and SAA ...... e isotype-specific PRM assays.
@en
P2093
P2860
P356
P1433
P1476
Quantification of SAA1 and SAA ...... he isotype-specific PRM assays
@en
P2093
Bruno Domon
Katriina Sertamo
Marc Schlesser
Panchali Goswami
Sebastien Gallien
Victoria El-Khoury
Yeoun Jin Kim
P2860
P304
P356
10.1002/PMIC.201400382
P50
P577
2015-08-17T00:00:00Z